GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » Cyclically Adjusted Revenue per Share

Grifols (MEX:GRF N) Cyclically Adjusted Revenue per Share : MXN0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Grifols Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Grifols's adjusted revenue per share for the three months ended in Dec. 2024 was MXN63.416. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Grifols's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Grifols was 10.80% per year. The lowest was 10.20% per year. And the median was 10.50% per year.

As of today (2025-07-08), Grifols's current stock price is MXN0.00. Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was MXN0.00. Grifols's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.93. And the median was 2.01.


Grifols Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Grifols's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Cyclically Adjusted Revenue per Share Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Grifols's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted PS Ratio falls into.


;
;

Grifols Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grifols's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=63.416/124.7533*124.7533
=63.416

Current CPI (Dec. 2024) = 124.7533.

Grifols Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 20.846 100.139 25.970
201406 20.685 101.081 25.529
201409 20.692 100.441 25.701
201412 24.287 100.251 30.223
201503 22.162 99.474 27.794
201506 24.957 101.138 30.784
201509 26.293 99.559 32.947
201512 28.701 100.268 35.710
201603 26.418 98.638 33.413
201606 29.638 100.333 36.852
201609 32.173 99.737 40.243
201612 34.976 101.842 42.844
201703 31.291 100.896 38.690
201706 33.523 101.848 41.062
201709 32.657 101.524 40.129
201712 36.326 102.975 44.009
201803 33.517 102.122 40.945
201806 37.294 104.165 44.665
201809 36.782 103.818 44.199
201812 38.868 104.193 46.538
201903 37.688 103.488 45.432
201906 39.840 104.612 47.511
201909 41.773 103.905 50.155
201912 41.227 105.015 48.976
202003 48.980 103.469 59.056
202006 56.446 104.254 67.545
202009 51.174 103.521 61.670
202012 45.928 104.456 54.852
202103 42.192 104.857 50.198
202106 47.374 107.102 55.181
202112 0.000 111.298 0.000
202206 48.330 118.044 51.077
202209 45.209 117.221 48.114
202212 52.140 117.650 55.288
202306 48.570 120.278 50.377
202309 43.731 121.343 44.960
202312 48.234 121.300 49.607
202406 48.312 124.409 48.446
202409 57.653 123.121 58.417
202412 63.416 124.753 63.416

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Grifols  (MEX:GRF N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.93. And the median was 2.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Grifols Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Grifols's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » Cyclically Adjusted Revenue per Share
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines